Transparency Market Research

Pulmonary Arterial Hypertension Market Expected to Expand Due to Rise in Incidence of Heart Failures

Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020


Albany, NY -- (SBWIRE) -- 06/03/2015 -- The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart. PAH is one of five groups of pulmonary hypertension, as described by the World Health Organization (WHO). PAH develops due to the narrowing, blocking, and thickening of the pulmonary arteries.

Browse Full Global Pulmonary Arterial Hypertension Market Report With Complete TOC @

Advanced treatment of PAH includes prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. This leading therapy is aimed towards the symptoms of PAH and is not directed at the fundamental cause of PAH. In addition to the aforementioned classification of drugs, there are some other drugs prescribed to patients suffering from PAH, such as diuretics, calcium channel blockers, anticoagulants, and digoxin.

The pulmonary arterial hypertension (PAH) market was valued at US$4.04 billion in 2013 and is expected reach US$5.19 billion in 2020, expanding at a CAGR of 2.3% between 2014 and 2020.

Uptravi: A New Drug Application in Patients with Pulmonary Arterial Hypertension

Categorized on the basis of substantially applicable drug categories, the global pulmonary arterial hypertension (PAH) market has been segregated into prostacyclin analogs and prostacyclin, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the foremost to be medically endorsed by the U.S. FDA to treat PAH. Presently, epoprostenol Veletri and Flolan, treprostinil (Tyvaso, Remodulin, and Orenitram), and iloprost (Ventavis) are the three primary drugs in this category, and are widely used in the treatment for patients with PAH. A new drug called Uptravi, which is an assorted IP prostacyclin antagonist, is predicted to come to the fore by 2016. This new drug is expected to augment the growth of the market for prostacyclin analogs and prostacyclin through the forecast period from 2014 to 2020.

Browse Full Presss Release Report:

Opsumit: The Highest Selling Pulmonary Arterial Hypertension Drug

Endothelin receptor antagonists (ERAs) that disrupt the interaction between endothelin receptors and endothelin have materialized as one of the primary segments in the treatment of PAH. Tracleer (bosentan) is the foremost FDA-certified ERA. Opsumit (macitentan) and Letairis/Volibris (ambrisentan) are some other certified ERAs for the treatment of PAH. Among these, Opsumit was certified by the European Commission and the U.S. FDA in December 2013. Opsumit is predicted to materialize as the highest selling PAH drug by the end of 2020. Tracleer is set to be off-patent in Europe and the U.S. in 2017 and 2015, respectively. Patent termination of Tracleer is expected to constitute a big setback in the advancement of the ERAs market from 2014 to 2020.

Adempas: The only Certified Stimulator by the U.S. FDA to Treat Pulmonary Hypertension

Adcirca (tadalafil) from Eli Lilly/United Therapeutics Corporation and Revatio (sildenafil) from Pfizer, Inc., are the FDA-certified PDE-5 inhibitors used for the treatment of PAH. Adempas (riociguat) is the only approved sGC blockage used for the treatment of PAH. Adempas is devised for the treatment of PAH by stimulation of nitric oxide receptor sGC, which causes vasodilation, relieving the pressure on arterial walls. Adempas was first certified by the U.S. FDA in October 2013. Throughout the forecast period from 2014 to 2020, riociguat would undergo extreme competition from drugs such as treprostinil and macitentan, as all of them are meant for oral application.

Leading players in the global pulmonary arterial hypertension (PAH) market include United Therapeutics Corporation, Gilead Sciences, GSK Plc, and Actelion Pharmaceuticals, Ltd. Among these, Actelion Pharma held the biggest share in the global PAH market in 2013 thanks to its top-selling product, Tracleer (bosentan).

Request a Brochure of this Report:

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.